Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact

Qublan, Hussein S.; Amarin, Zouhair; Tahat, Yousef; Smadi, Aiman Z.; Kilani, M.

doi:10.1093/humrep/dei371

Cited by 63 publications

(39 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence varies between 5.5% and 53% in different studies (1,4,5,8,12 ). In a recent study performed by Qublan et al (4), the rate was reported as 9.3% in a large population of IVF patients, which was consistent with our results, at 8.3%.…”

Section: Discussionsupporting

confidence: 92%

“…Such ovarian cysts are still being discussed in terms of their proper management and their impact on the IVF outcome. Mechanical pressure on the ovarian tissue that reduces the area for growing follicles and the decreased blood circulation in and around the follicles are physical explanations for their negative impacts (1)(2)(3)(4). Another likely problem concerning these ovarian cysts may be endocrinological in nature.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles

Eryılmaz¹,

Sarıkaya²,

Aksakal³

et al. 2012

Balkan Med J

View full text Add to dashboard Cite

Objective: The gonadotropin-releasing hormone-agonist (GnRH-a) treatment during in vitro fertilization (IVF) sometimes causes a functional ovarian cyst during the administration period before gonadotropin stimulation, as an undesired event. The aim of this study was to analyze the effect of these cysts on the IVF outcomes. Materials and Methods:Out of 981 IVF cycles, 78 with ovarian cysts were retrospectively analyzed with respect to the demographic characteristics, hormonal outcomes, and fertilization, implantation and clinical pregnancy rates.Results: The metaphase II oocyte ratio, fertilization rate and percentage of high quality embryos (grade 1) were significantly higher in the cyst-negative group (p<0.0001; p<0.0001; p≤0.05). These same three parameters were also significantly higher in the cyst-aspirated group (p<0.01; p<0.05; p<0.05). Cyst diameters of the aspiration group were significantly higher (p<0.05). No statistically significant differences in implantation and clinical pregnancy rates were determined between the groups.Conclusion: An ovarian cyst formation during the GnRH-a suppression period negatively affects oocyte quality. Cyst aspiration before gonadotropin stimulation does not improve the IVF outcome.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles

Eryılmaz¹,

Sarıkaya²,

Aksakal³

et al. 2012

Balkan Med J

View full text Add to dashboard Cite

show abstract

“…Study participants were between the ages of 25 and 44 years and had a body mass index (BMI) from 17 to 28.5 kg/m 2 . Exclusion criteria were galactorrhea, endometriomas, or ovarian cysts greater than 18 mm in diameter as possible modifiers of ovarian responsiveness to gonadotropin therapy (25, 26). Women undergoing IVF who were obese (BMI ≥ 30) were also excluded to eliminate confouding effects of obesity on ovarian cell lipid content or steroidogenesis (8, 27, 28).…”

Section: Methodsmentioning

confidence: 99%

Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization

Simerman

Hill

Grogan

et al. 2015

Fertility and Sterility

View full text Add to dashboard Cite

Objective To determine whether follicular fluid (FF) cortisol levels affect cumulus cell (CC) lipid content during oocyte meiotic resumption and whether CCs express genes for glucocorticoid action. Design Prospective cohort study Setting Academic medical center Patients Thirty-seven non-obese women underwent ovarian stimulation for IVF Intervention(s) At oocyte retrieval, FF was aspirated from the first follicle (>16 mm in size) of each ovary and pooled CC were collected. Main Outcome Measure(s) FF cortisol and cortisone analysis was performed by liquid chromatography-tandem mass spectrometry. CCs were stained with lipid fluorescent dye BODIPY FL C16 to determine lipid content by confocal microscopy. Quantitative real-time PCR was used to detect CC gene expression of 11β-hydroxysteroid dehydrogenase (11βHSD) types 1 and 2, glucocorticoid receptor (NR3C1), lipoprotein lipase (LPL) and hormone sensitive lipase (HSL). Results Adjusting for maternal age, FF cortisol levels negatively correlated with CC lipid content and positively correlated with numbers of total and mature oocytes. CCs expressed genes for 11βHSD type 1 as the predominant 11βHSD isoform, NR3C1, LPL and HSL. Conclusion FF cortisol levels may regulate CC lipolysis during oocyte meiotic resumption and affect oocyte quality during IVF.

show abstract

“…The couple returned for a second cycle of IVF using same long protocol but down regulation could not be achieved due to ovarian cyst formation, a well-recognized complication of GnRH-a therapy [3]. This cycle of treatment was stopped.…”

Section: Case Reportmentioning

confidence: 99%

First Irish birth following IVF therapy using antagonist protocol

et al. 2009

View full text Add to dashboard Cite

show abstract

Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact

Cited by 63 publications

References 18 publications

Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles

Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles

Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization

First Irish birth following IVF therapy using antagonist protocol

Contact Info

Product

Resources

About